Abstract

) The Prostate and Urologic Cancer Program (PUCP) of the UPCI focuses on the basic and clinical study of prostate and other genitourinary (GU) cancers. The Program's goals are (1) to develop improved understanding of the biology of prostate and other GU cancers; (2) to develop new diagnostic and therapeutic approaches to these tumors; and (3) to develop new concepts applicable to the prevention of prostate or other GU cancers. These goals are approached through basic science investigations, translational research studies, and clinical trials. The leadership of the Program consists of Dr. Robert H. Getzenberg, Assistant Professor of Pathology, Surgery, Medicine and Pharmacology and Director of Research, PUCP and Dr. Donald L. Trump, Professor of Medicine and Surgery, Chief of the Division of Hematology/Oncology and UPCI Deputy Director for Clinical Investigations. The PUCP is a very interactive program including members of Urology, Hematology/Oncology, Endocrinology, Pathology and other basic science and clinical departments, all actively participating in the Program. Many of the grants and papers resulting from the Program are cooperative efforts among PUCP members.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA047904-12
Application #
6212115
Study Section
Subcommittee G - Education (NCI)
Project Start
1988-08-01
Project End
2004-07-30
Budget Start
Budget End
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213

  Publications

Sun, Weijing; Patel, Anuj; Normolle, Daniel et al. (2018) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer :
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:
Christner, Susan; Guo, Jianxia; Parise, Robert A et al. (2018) Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. J Pharm Biomed Anal 150:169-175
Laymon, Charles M; Minhas, Davneet S; Becker, Carl R et al. (2018) Image-Based 2D Re-Projection for Attenuation Substitution in PET Neuroimaging. Mol Imaging Biol 20:826-834
Benoist, Guillemette E; van der Meulen, Eric; van Oort, Inge M et al. (2018) Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Ther Drug Monit 40:222-229
Singh, Krishna B; Hahm, Eun-Ryeong; Rigatti, Lora H et al. (2018) Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate. Cancer Prev Res (Phila) 11:337-346
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Thakur, Prakash C; Miller-Ocuin, Jennifer L; Nguyen, Khanh et al. (2018) Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med 16:190
Posluszny, Donna M; Bovbjerg, Dana H; Agha, Mounzer E et al. (2018) Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen. Psychooncology 27:354-358

Showing the most recent 10 out of 1187 publications